AMGN

Amgen Inc

365.84

USD

AMGN Earnings Reports

Positive Surprise Ratio

AMGN beat 36 of 40 last estimates.

90%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$8.79B

$4.87

Implied change from Q4 25 (Revenue/ EPS)

-10.95%

-7.94%

Implied change from Q1 25 (Revenue/ EPS)

+7.81%

-0.61%

Amgen Inc earnings per share and revenue

On Feb 03, 2026, AMGN reported earnings of 5.29 USD per share (EPS) for Q4 25, beating the estimate of 4.82 USD, resulting in a 9.56% surprise. Revenue reached 9.87 billion, compared to an expected 9.66 billion, with a 2.12% difference. The market reacted with a +8.15% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 13 analysts forecast an EPS of 4.87 USD, with revenue projected to reach 8.79 billion USD, implying an decrease of -7.94% EPS, and decrease of -10.95% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Mineralys Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.40

Surprise

+26.40%

Corvus Pharmaceuticals, Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.15

Surprise

-13.72%

Pharming Group N.V. ADS, each representing 10 ordinary shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.00

Actual

$0.01

Surprise

+16.28%

ADC Therapeutics SA

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.04

Surprise

+85.39%

Kamada Ltd

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.07

Actual

$0.06

Surprise

-24.15%

Allogene Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.17

Surprise

+22.73%

Molecular Partners AG - ADR

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.32

Surprise

+7.09%

Whitehawk Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.15

Actual

-$0.34

Surprise

-116.42%

Codexis, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.04

Actual

$0.11

Surprise

+357.01%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

FAQ

What were Amgen Inc's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Amgen Inc reported EPS of $5.29, beating estimates by 9.56%, and revenue of $9.87B, 2.12% above expectations.

How did the market react to Amgen Inc's Q4 2025 earnings?

The stock price moved up 8.15%, changed from $338.59 before the earnings release to $366.20 the day after.

When is Amgen Inc expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Amgen Inc's next earnings report?

Based on 13 analysts, Amgen Inc is expected to report EPS of $4.87 and revenue of $8.79B for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.